mannkind corporation danbury, ct

Average salary for MannKind Corporation Director in Danbury: $213,299. United States » Connecticut » Fairfield County » Danbury » Is this your business? With our ultra rapid-acting inhaled insulin, Afrezza®, we are changing the way diabetes is treated and, with our innovative and powerful Technosphere® technology, we are developing new ways for people with orphan and other serious lung diseases to take control of their health. IND for Technosphere insulin submitted to the U.S. FDA; PDC relocates to Danbury, CT. Glucose clamp clinical study of Technosphere insulin conducted in Germany. MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin. A free inside look at company reviews and salaries posted anonymously by employees. Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies. Privacy Policy Find 1 listings related to Mannkind Corp in Danbury on YP.com. We are driven to find new ways to change lives for the better. Our therapeutic innovations are empowering people to take control of their health and get the most out of life. Ms. Grancio will also serve as a member of the Audit Committee of the Board. Pharmaceutical Discovery Corporation (PDC) is incorporated; establishes a R&D facility in Elmsford, NY. ","language":"en","releaseDate":{"dateUTC":"2018-10-25T21:00:00","date":"2018-10-25T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2018 Third Quarter Financial Results Conference Call on November 1, 2018","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15896/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-10-25T21:03:10","lastUpdatedUTC":"2018-10-25T21:03:10"},{"id":15886,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15886","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/united-therapeutics-and-mannkind-announce-closing-license-and"},"title":"United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement","type":{"title":"General","id":3886},"teaser":"RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif. , Oct. 16, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the","language":"en","releaseDate":{"dateUTC":"2018-10-16T10:00:00","date":"2018-10-16T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15886/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-10-16T10:02:46","lastUpdatedUTC":"2018-10-16T10:02:46"},{"id":15876,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15876","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/afrezzar-inhaled-insulin-television-advertising-campaign-wins"},"title":"Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity","type":{"title":"General","id":3886},"teaser":"Broadcast spot recognized at 2018 Medical Marketing & Media (MM&M) Awards WESTLAKE VILLAGE, Calif. , Oct. 15, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as","language":"en","releaseDate":{"dateUTC":"2018-10-15T13:00:00","date":"2018-10-15T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15876/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-10-15T13:04:32","lastUpdatedUTC":"2018-10-15T13:04:32"},{"id":15871,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15871","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-positive-afrezzar-stat-study-clinical-data"},"title":"MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes","type":{"title":"General","id":3886},"teaser":"Poster 813; PS 068  Improved post-prandial blood glucose excursions with Technosphere inhaled insulin compared to aspart in adult patients with type 1 diabetes: STAT study intention to treat analysis Poster 677; PS 051 Improved time-in-range on continuous glucose monitor with Technosphere insulin","language":"en","releaseDate":{"dateUTC":"2018-10-04T13:00:00","date":"2018-10-04T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15871/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-10-04T13:02:32","lastUpdatedUTC":"2018-10-04T13:02:32"},{"id":15866,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15866","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-new-scientific-data-54th-annual-meeting"},"title":"MannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes","type":{"title":"General","id":3886},"teaser":"Presentation 55  Total and severe hypoglycemia is reduced with use of inhaled Technosphere® Insulin (TI) relative to insulin aspart in type 1 diabetes Poster 1046; PS 097  Diabetes duration, BMI, and HbA1c have greater effects on Pulmonary Function (PF) than inhaled Technosphere® Insulin (TI)  ","language":"en","releaseDate":{"dateUTC":"2018-10-03T13:00:00","date":"2018-10-03T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15866/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-10-03T13:04:13","lastUpdatedUTC":"2018-10-03T13:04:13"},{"id":15851,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15851","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-completion-cohort-1-and-opens-enrollment"},"title":"MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today that Cohort 2 of the Afrezza® safety and pharmacokinetics study in pediatric patients is now open for enrollment. ©2021 MannKind Corporation. It maintains a campus in Danbury, Conn. The","language":"en","releaseDate":{"dateUTC":"2019-07-18T12:52:00","date":"2019-07-18T08:52:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16466/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-07-18T12:53:05","lastUpdatedUTC":"2019-07-18T12:53:05"},{"id":16461,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16461","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-partners-goodrx-help-raise-awareness-reducing-out"},"title":"MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients","type":{"title":"General","id":3886},"teaser":"More than 65,000 patients pay over $200 per month for their mealtime insulin Commercially insured patients can pay as little as $15 per month for inhaled insulin Underinsured and uninsured patients can pay as little as $5 a day with MannKind direct purchase program  WESTLAKE VILLAGE, Calif., July","language":"en","releaseDate":{"dateUTC":"2019-07-15T13:00:00","date":"2019-07-15T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16461/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-07-15T13:01:40","lastUpdatedUTC":"2019-07-15T13:01:40"},{"id":16456,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16456","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-expands-commercial-scale-manufacturing-capabilities"},"title":"MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 11, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has","language":"en","releaseDate":{"dateUTC":"2019-07-11T20:14:00","date":"2019-07-11T16:14:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16456/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-07-11T20:15:24","lastUpdatedUTC":"2019-07-11T20:15:24"},{"id":16446,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16446","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-present-jmp-securities-life-sciences-conference"},"title":"MannKind to Present at the JMP Securities Life Sciences Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 12, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2019-06-12T13:00:00","date":"2019-06-12T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Present at the JMP Securities Life Sciences Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16446/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-06-12T13:05:11","lastUpdatedUTC":"2019-06-12T13:05:11"},{"id":16441,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16441","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-positive-afrezzar-clinical-data-three-studies"},"title":"MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 09, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being held June 7-11,","language":"en","releaseDate":{"dateUTC":"2019-06-09T18:00:00","date":"2019-06-09T14:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16441/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-06-09T18:00:56","lastUpdatedUTC":"2019-06-09T18:00:56"},{"id":16436,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16436","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/afrezzar-insulin-human-inhalation-powder-approved-brazil"},"title":"Afrezza® (insulin human) Inhalation Powder Approved in Brazil","type":{"title":"General","id":3886},"teaser":"Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. For more information, visit https://afrezza.com/coronavirus/, MannKind regains commercial rights to Afrezza, Additional Phase 3 studies of Technosphere insulin conducted using next-generation inhaler (Dreamboat. PDC merges with two other Mann-affiliated biopharmaceutical companies–CTL ImmunoTherapies Corp. and AlleCure Corp–the surviving company is named MannKind Corporation. Patent Notices Ms. Mundkur will also serve as a member of the Audit Committee of the Board. 818.661.5000, Terms of Use Our mission is to give people control over their health and the freedom to live life. At this time, MannKind does not anticipate that the supply of its inhalable insulin Afrezza® (insulin human) Inhalation Powder will be affected by the coronavirus. 818.661.5000, contact@mannkindcorp.com Ms.","language":"en","releaseDate":{"dateUTC":"2018-11-27T14:00:00","date":"2018-11-27T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Appoints Christine Mundkur to its Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15946/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-11-27T14:05:18","lastUpdatedUTC":"2018-11-27T14:05:18"},{"id":15906,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15906","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2018-third-quarter-financial"},"title":"MannKind Corporation Reports 2018 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET Executed license and collaboration agreement with United Therapeutics for up to $95 million in upfront and milestone payments plus royalties Executed research agreement for a second Technosphere formulation with United Therapeutics for $10 million Fifth","language":"en","releaseDate":{"dateUTC":"2018-11-01T12:00:00","date":"2018-11-01T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2018 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15906/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-11-01T12:06:38","lastUpdatedUTC":"2018-11-01T12:06:38"},{"id":15896,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15896","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2018-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2018 Third Quarter Financial Results Conference Call on November 1, 2018","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host a conference call to discuss the 2018 third quarter and year-to-date financial results and other corporate developments at 9:00 AM (Eastern Time) on Thursday, November 1, 2018 . MannKind is currently commercializing Afrezza® … Apply on company website. Alfred E. Mann was a visionary in aerospace, medical technology, and biopharmaceuticals, but his true passion was helping people. Wooster School Danbury Ct was established in 1926. Patent Notices has been appointed to its Board of Directors, effective December 1, 2020. 2004; 2001. MannKind Corporation NDA for Technosphere insulin is submitted to the FDA. As the global situation evolves, we will continue to take the necessary steps to safeguard the reliable supply of Afrezza. MannKind Corporation, Danbury, CT 06810. All rights reserved. MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin. TRANSMITTED BY FACSIMILE. 2 MannKind Corporation jobs in Danbury, CT. Search job openings, see if they fit - company salaries, reviews, and more posted by MannKind Corporation employees. 3 customer reviews of Mannkind Corporation. Apply on company website. Additional Phase 3 studies of Technosphere insulin conducted using next-generation inhaler (Dreamboat®). ©2021 MannKind Corporation. Corporate Governance. Reviews (203) 798-8000 Website. 818.661.5000, Terms of Use Commercial manufacturing facility in Danbury is expanded and renovated. In Europe and the U.S. alone, it is estimated 15 to 20 million patients a year visit the emergency departments of hospitals","language":"en","releaseDate":{"dateUTC":"2018-09-05T12:30:00","date":"2018-09-05T08:30:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Innovative Diagnostic Technology Playing Significant Role in Improving Detection for Better Cardiac Care","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15821/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-09-05T12:33:33","lastUpdatedUTC":"2020-04-22T01:43:14"},{"id":15806,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15806","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/united-therapeutics-and-mannkind-announce-collaboration-0"},"title":"United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products","type":{"title":"General","id":3886},"teaser":"Exclusive license agreement for Treprostinil Technosphere®; $95 million in upfront and milestone payments Research agreement for additional products for additional $10 million SILVER SPRING, Md. Dr.  Kay will also serve as a member of the Audit Committee of the Board. During his career, he founded 17 companies and developed breakthrough medical devices, including cardiac pacemakers, insulin pumps, cochlear implants, retinal prostheses, and other technologies that enabled people to live fuller, healthier lives. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. PDC files the first patents for Technosphere® Technology. See More. Learn about our treatment option for patients with type 1 and type 2 diabetes, utilizing our needle-free, inhaled Technosphere® Technology, and the support we offer for patients with a prescription. ","language":"en","releaseDate":{"dateUTC":"2018-07-27T13:00:00","date":"2018-07-27T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2018 Second Quarter Financial Results Conference Call on August 2, 2018","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15686/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-07-27T13:04:55","lastUpdatedUTC":"2018-07-27T16:39:30"},{"id":15661,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15661","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-set-join-russell-3000r-index"},"title":"MannKind Set to Join Russell 3000® Index","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced it is set to","language":"en","releaseDate":{"dateUTC":"2018-06-25T13:00:00","date":"2018-06-25T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Set to Join Russell 3000® Index","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15661/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-06-25T13:02:48","lastUpdatedUTC":"2018-06-25T13:02:48"},{"id":15656,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15656","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/additional-positive-afrezzar-clinical-data-stat-study-be"},"title":"Additional Positive Afrezza® Clinical Data from STAT Study To Be Presented at ADA 78th Scientific Sessions","type":{"title":"General","id":3886},"teaser":"Oral presentation (348-OR) at 5:00 pm today Afrezza provides greater improvement in post-prandial glucose control than insulin aspart WESTLAKE VILLAGE, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced that additional data for Afrezza from the STAT study ( ST","language":"en","releaseDate":{"dateUTC":"2018-06-25T12:00:00","date":"2018-06-25T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Additional Positive Afrezza® Clinical Data from STAT Study To Be Presented at ADA 78th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15656/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-06-25T12:04:49","lastUpdatedUTC":"2018-06-25T15:19:11"},{"id":15651,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15651","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-positive-afrezzar-clinical-data-stat-and"},"title":"MannKind Presents Positive Afrezza® Clinical Data from STAT and AFFINITY Studies at ADA 78th Scientific Sessions","type":{"title":"General","id":3886},"teaser":"Poster 1017-P:  Afrezza provides improved Time-in-Range on Continuous Glucose Monitoring compared to insulin aspart Poster 102-LB:  Hypoglycemia is reduced with use of Afrezza compared to insulin aspart WESTLAKE VILLAGE, Calif. , June 23, 2018 (GLOBE NEWSWIRE) --   MannKind Corporation","language":"en","releaseDate":{"dateUTC":"2018-06-23T14:00:00","date":"2018-06-23T10:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Afrezza® Clinical Data from STAT and AFFINITY Studies at ADA 78th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15651/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-06-23T14:02:57","lastUpdatedUTC":"2018-06-23T14:02:57"},{"id":15641,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15641","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-host-institutional-investor-and-analyst-meeting"},"title":"MannKind to Host Institutional Investor and Analyst Meeting","type":{"title":"General","id":3886},"teaser":"Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes MannKind’s Chief Medical Officer Presenting New Afrezza ® Data Released at American Diabetes Association’s 78 th Scientific Sessions WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2018-06-20T20:01:00","date":"2018-06-20T16:01:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Host Institutional Investor and Analyst Meeting","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15641/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-06-20T20:05:03","lastUpdatedUTC":"2018-06-20T20:05:03"},{"id":15591,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15591","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-successfully-completes-phase-1-trial-treprostinil"},"title":"MannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension Advancing Development to Next Phase","type":{"title":"General","id":3886},"teaser":"Study achieved primary endpoint of safety and tolerability Progressive dosing of Treprostinil Technosphere (TreT) significantly exceeded the corresponding peak plasma and exposure levels of the maximum recommended dose of Tyvaso® Inhalation Solution Achieved a maximum tolerated dose with no serious","language":"en","releaseDate":{"dateUTC":"2018-06-07T13:00:00","date":"2018-06-07T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension Advancing Development to Next Phase","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15591/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-06-07T13:03:16","lastUpdatedUTC":"2018-06-07T13:03:16"},{"id":15586,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15586","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-establishes-market-price-stock-purchase-plan"},"title":"MannKind Establishes Market Price Stock Purchase Plan","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 05, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) has established a stock purchase plan that provides MannKind’s directors and executive officers with a way to purchase shares of common stock directly from the Company at the prevailing market price at","language":"en","releaseDate":{"dateUTC":"2018-06-05T20:30:00","date":"2018-06-05T16:30:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Establishes Market Price Stock Purchase Plan","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15586/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-06-05T20:33:41","lastUpdatedUTC":"2018-06-05T20:33:41"},{"id":15436,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15436","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2018-first-quarter-financial"},"title":"MannKind Corporation Reports 2018 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET Q1 2018 Afrezza Net Revenue was $3.4 million ; +184% vs. Q1 2017 (+234% under the 2017 revenue recognition model) Q1 2018 Net Cash Used in Operating Activities was $21.7 million STAT study results accepted for presentation at American Diabetes","language":"en","releaseDate":{"dateUTC":"2018-05-09T20:01:00","date":"2018-05-09T16:01:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2018 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15436/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-05-09T20:05:00","lastUpdatedUTC":"2018-05-09T20:05:00"},{"id":15431,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15431","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-cipla-enter-exclusive-marketing-and-distribution"},"title":"MannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza® in India","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced an exclusive","language":"en","releaseDate":{"dateUTC":"2018-05-09T13:00:00","date":"2018-05-09T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza® in India","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15431/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-05-09T13:03:55","lastUpdatedUTC":"2018-05-09T15:16:10"},{"id":15426,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15426","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2018-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2018 First Quarter Financial Results Conference Call on May 9, 2018","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , May 02, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2018 first quarter financial results on Wednesday, May 9, 2018 and its management will host a conference call to discuss the financial results and other Company developments at 5:00 PM","language":"en","releaseDate":{"dateUTC":"2018-05-02T13:00:00","date":"2018-05-02T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2018 First Quarter Financial Results Conference Call on May 9, 2018","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15426/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-05-02T13:03:49","lastUpdatedUTC":"2018-05-07T19:54:18"},{"id":15416,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15416","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/fda-determines-afrezza-rems-communication-plan-has-met-goals-and"},"title":"FDA Determines that Afrezza REMS Communication Plan Has Met Goals and REMS No Longer Necessary","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that the Food and Drug","language":"en","releaseDate":{"dateUTC":"2018-04-25T20:30:00","date":"2018-04-25T16:30:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"FDA Determines that Afrezza REMS Communication Plan Has Met Goals and REMS No Longer Necessary","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15416/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-04-25T20:34:07","lastUpdatedUTC":"2018-05-07T20:12:53"},{"id":15411,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15411","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-completion-previously-announced-280-million"},"title":"MannKind Announces Completion of Previously Announced $28.0 Million Registered Direct Offering","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 09, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced the completion of its previously announced registered direct offering of 14,000,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common","language":"en","releaseDate":{"dateUTC":"2018-04-09T20:10:00","date":"2018-04-09T16:10:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Completion of Previously Announced $28.0 Million Registered Direct Offering","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15411/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-04-09T20:12:20","lastUpdatedUTC":"2018-05-07T20:12:57"},{"id":15386,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15386","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-280-million-registered-direct-offering"},"title":"MannKind Announces $28.0 Million Registered Direct Offering","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 06, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced the pricing of a registered direct offering of 14,000,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common stock to select healthcare","language":"en","releaseDate":{"dateUTC":"2018-04-06T05:58:00","date":"2018-04-06T01:58:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces $28.0 Million Registered Direct Offering","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15386/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-04-06T06:02:00","lastUpdatedUTC":"2018-05-07T20:13:31"},{"id":15361,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15361","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-participation-hc-wainwright-annual-global"},"title":"MannKind Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced it will be featured as a","language":"en","releaseDate":{"dateUTC":"2018-03-19T12:00:00","date":"2018-03-19T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15361/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-03-19T12:03:01","lastUpdatedUTC":"2018-05-07T20:13:36"},{"id":15356,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15356","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-oppenheimer-28th-annual-healthcare"},"title":"MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 14, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that its Chief Executive","language":"en","releaseDate":{"dateUTC":"2018-03-14T12:00:00","date":"2018-03-14T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15356/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-03-14T12:03:02","lastUpdatedUTC":"2018-05-07T20:13:40"},{"id":15351,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15351","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-stat-study-results-accepted-presentation"},"title":"MannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific Sessions","type":{"title":"Earnings","id":3896},"teaser":"WESTLAKE VILLAGE, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that research results","language":"en","releaseDate":{"dateUTC":"2018-03-13T12:00:00","date":"2018-03-13T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15351/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2018-03-13T12:04:38","lastUpdatedUTC":"2018-05-07T20:13:46"},{"id":15341,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/15341","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-restructures-797-million-debt-obligation-mann-group-and"},"title":"MannKind Restructures $79.7 Million Debt Obligation to the Mann Group and Reduces Principal Owed to Deerfield by $6.3 Million","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the restructuring of certain of its outstanding debt obligations, reducing outstanding principal by an aggregate of $14.5 million along with the corresponding interest expense.

Watch Team Canada World Juniors Online, Veterans Benefits Administration Organizational Chart, Canal Lake Walleye, Jill Schupp Net Worth, Cis Lol Region, Worldpay Business Gateway, Child Benefit Payment Dates 2021 Uk, Sgx Yahoo Finance, Afl Same Game Multi,